Clinical trials: Substance Withdrawal
Cannabis Dependence, Alcohol Dependence
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence.
- Conditions
- Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
- Trial name
- NCT02210195
- Testing
- aprepitant, Manual-guided behavioral counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Scripps Research Institute
Cannabis Use Disorder, Cannabis Withdrawal
Progesterone for Cannabis Withdrawal
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options.
- Trial name
- NCT03430050
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical University of South Carolina
Substance Withdrawal Syndrome
Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Prescription opioid addiction is a growing public health problem and more pharmacologic treatments are needed because current approved medications have had limited patient acceptance (naltrexone), limited availability…
- Trial name
- NCT00980044
- Testing
- Tramadol
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Michelle Lofwall
Opioid Dependence, Opioid Withdrawal
Oxytocin Treatment of Opioid Dependence
Purpose: The purpose of this research study is to learn whether oxytocin treatment decreases use of and cravings for opioids (narcotics) in people who have been using opioids heavily for long periods of time and are unable to…
- Trial name
- NCT02548728
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
Tobacco Use Disorder
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions.
- Trial name
- NCT04090879
- Testing
- Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g), E-Cigarettes
- Where
- 2 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Brown University
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Opioid-Related Disorders
Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Repeated use and/or abuse of opioid medications is generally associated with a characteristic withdrawal syndrome that develops after cessation of drug administration.
- Trial name
- AV411 (NCT00723177)
- Testing
- AV411
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Tobacco Use Disorder
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Prevalence of smoking among individuals with opioid use disorder (OUD) is six-fold that of the general US adult population. The mortality rate of opioid-dependent smokers is four times that of opioid-dependent nonsmokers, and…
- Trial name
- NCT04092101
- Testing
- Cigarettes with varying nicotine content, E-Cigarettes
- Where
- 2 sites in United States
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Delirium, Psychomotor Agitation
Nicotine Replacement Therapy in the Intensive Care Unit
The purpose of this study is to determine whether transdermal nicotine replacement therapy is safe and effective for treating nicotine withdrawal symptoms in the critically ill smoking patient.
- Conditions
- Delirium, Psychomotor Agitation, Substance Withdrawal Syndrome, Nicotine Replacement Therapy
- Trial name
- NicGoWell (NCT01362959)
- Testing
- Transdermal nicotine patch, Cutaneous patch, containing no active substances
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people
- Sponsor
- Gelderse Vallei Hospital
Neonatal Abstinence Syndrome
Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal
Hypothesis is that the effectiveness of opiate treatment with morphine will result in shorter duration of opiate medication treatment and fewer infants treated with a second drug.
- Trial name
- NAS (NCT01804075)
- Testing
- Methadone, Morphine
- Volunteers
- 31 people
- Sponsor
- Eastern Maine Medical Center
Opioid-use Disorder
Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone
This study compares two methods of initiating treatment with extended-release naltrexone (XR-NTX) when implemented at community-based inpatient or residential programs.
- Trial name
- SWIFT (NCT04762537)
- Testing
- Standard Induction Procedure (SP), Rapid Induction Procedure (RP)
- Where
- 6 sites in United States
- Volunteers
- 415 people
- Sponsor
- New York State Psychiatric Institute
Cannabis Dependence, Marijuana Dependence
Nabilone for Cannabis Dependence: A Pilot Study
Cannabis use disorders are an important public health problem in the United States, but there are no effective medications available to treat these disorders.
- Trial name
- NAB CAN (NCT01347762)
- Testing
- Nabilone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mclean Hospital
Alcoholism, Alcohol Withdrawal
Preventing Alcohol Withdrawal With Oral Baclofen
The purpose of this study is determine if the medication baclofen can prevent the symptoms of Alcohol Withdrawal Syndrome (AWS) in hospitalized patients who may be at risk for AWS.
- Trial name
- BACLOFEN III (NCT01937364)
- Testing
- Baclofen
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Essentia Health
Alcohol-Related Disorders, Alcohol Dependence
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Trial name
- NCT00106106
- Testing
- NMR-spectroscopy, Oral acamprosate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Tobacco Use Disorder
Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders
This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Adults with affective disorders are at increased risk for smoking, nicotine dependence, and using high nicotine yield…
- Trial name
- NCT02232737
- Testing
- Very low nicotine content cigarettes
- Where
- 2 sites in United States
- Volunteers
- 775 people, healthy volunteers welcome
- Sponsor
- Brown University
Cannabis Dependence, Cannabis Withdrawal
Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
The purpose of this study is to find out more about cognitive functioning in people who are cannabis dependent, relative to people who do not use cannabis, and how their brains process information after one month of not using…
- Trial name
- SCCAN (NCT00656487)
- Testing
- rimonabant
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- The Scripps Research Institute
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc